ME02600B - Imunogena kompozicija - Google Patents
Imunogena kompozicijaInfo
- Publication number
- ME02600B ME02600B MEP-2017-26A MEP201726A ME02600B ME 02600 B ME02600 B ME 02600B ME P201726 A MEP201726 A ME P201726A ME 02600 B ME02600 B ME 02600B
- Authority
- ME
- Montenegro
- Prior art keywords
- toxin
- proximal end
- amino acids
- polypeptide according
- polypeptide
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 9
- 229920001184 polypeptide Polymers 0.000 claims 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 235000001014 amino acid Nutrition 0.000 claims 37
- 229940024606 amino acid Drugs 0.000 claims 37
- 150000001413 amino acids Chemical class 0.000 claims 37
- 101710182223 Toxin B Proteins 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 18
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 16
- 101710182532 Toxin a Proteins 0.000 claims 16
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (40)
- l. Polipeptid koji sadrži prvi fragment i drugi fragment,gde(i) prvi fragment je fragment ponavljajućeg domena toksina A;(ii) drugi fragment je fragment ponavljajućeg domena toksina B; (iii) prvi fragment ima prvi proksimalni (susedni) kraj;(iv) drugi fragment ima drugiproksimalni(susedni) kraj igde su prvi fragment i drugi fragment odvojeni sa manje od ili tačno sa S amino-kiselina u primarnoj strukturi, gde polipeptid indukuje antitela koja neutralizuju oba toksina A i B, gde je prvi proksimalni kraj u okviru kratkog ponovka, drugi proksimalni kraj je u okviru kratkog ponovka i prvi proksimalni kraj i drugi proksimalni kraj ne remete motiv ponovaka kratko dugačko-kratko.
- 2. Polipeptid prema zahtevu 1, gde polipeptid indukuje zaštitni imuni odgovor kod domaćina sisara protiv soja C.difficile..
- 3. Polipeptid prema bilo kom od zahteva 1-2, gde prvi fragment i/ili drugi fragment sadrže manje od 2S%, 20%, 18% ili lS% alfa helikoidne strukture..
- 4. Polipeptid prema bilo kom prethodnom zahtevu, gde prvi fragment i/ili drugi fragment sadrže više od 2S%,30%, 3S%,38% ili 40% beta nabrane strukture.
- 5. Polipeptid prema bilo kom prethodnom zahtevu, gde prvi proksimalni kraj nije u okviru amino-kiselina 1878-1940, 2012-2074, 2146-2208, 22S8-2322, 2394-2456, 2507-2569 ili 2598-2660 toksina A.
- 6 Polipeptid prema bilo kom od prethodnog zahteva, gde drugi proksimalni kraj nije u okviru amino-kiselina 1881-1942,2012-2074,2144-2208 ili 2278-2339 toksina B.
- 7. Polipeptid prema bilo kom prethodnom zahtevu, gde prvi fragment ima bar 100, 250, 400 ili 450 amino-kiselina.
- 8. Polipeptid prema bilo kom prethodnom zahtevu,gde drugi fragment ima bar 100, 200,300 ili 400 amino-kiselina.
- 9. Polipeptid prema bilo kom prethodnom zahtevu, gde je prvi proksimalni kraj u okviru ponavljajućeg motiva VIlI (amino-kiselina 2645-2710) toksina A.
- 10. Polipeptid prema bilo kom od zahteva 1-9, gde je prvi proksimalni kraj u okviru amino kiselina 2700-2710 ili 2680-2690 toksina A.
- 11. Polipeptid prema bilo kom prethodnom zahtevu, gde je drugi proksimalni kraj u ovkiru ponavljajućeg motiva l (amino-kiselina 1834-1926) toksina B.
- 12. Polipeptid prema bilo kom prethodnom zahtevu, gde je drugi proksimalni kraj u okviru amino-kiselina 1860-1878 ili 1854-1876 toksina B.
- 13. Polipeptid prema bilo kom od zahteva 1-10, gde je drugi proksimalni kraj u okviru ponavljajućeg motiva ll (amino-kiselina 1927-2057) toksina B.
- 14. Polipeptid prema bilo kom od zahteva 1-10 ili 13, gde je drugi proksimalni kraj u okviru amino-kiselina 1960-1970, 1988-1998 ili 1867-1877 toksina B.
- 15. Polipeptid prema bilo kom od zahteva 9, 10, llili 12, gde je prvi proksimalni kraj u okviru ponavljajućeg motiva VIII (amino-kiselina 2645-2710) toksina A i gde je drugi proksimalni kraj u okviru ponavljajućeg motiva l (amino-kiselina 1834-1926) toksina B.
- 16. Polipeptid prema bilo kom od zahteva 9, 10, 13 ili 14, gde je prvi proksimalni kraj u okviru ponavljajućeg motiva VIll (amino-kiselina 2645-2710) toksina A i gde je drugi proksimalni kraj u okviru ponavljajućeg motiva ll (amino-kiselina 1927-2057) toksina B.
- 17. Polipeptid prema bilo kom od zahteva 9, 10, 13 ili 14, gde je prvi proksimalni kraj u okviru kratkog ponovka 3 ponavljajućeg motiva VIII toksina A (amino-kiselina 2687-2710) i drugi proksimalni kraj je u okviru kratkog ponovka 4 ponavljajućeg motiva ll toksina B (amino kiselina 1988-2007).
- 18. Polipeptid prema bilo kom od zahteva 9, 10, 13 ili 14, gde je prvi proksimalni kraj u okviru kratkog ponovka 2 ponavljajućeg motiva VIII (amino-kiselina 2665-2686) toksina A i drugi proksimalni kraj je u okviru kratkog ponovka 3 ponavljajućeg motiva ll toksina B (amino kiselina 1968-1987).
- 19. Polipeptid prema bilo kom od zahteva 9,10, 11 ili 12,gde je prvi proksimalni u okviru kratkog ponovka 2 ponavljajućeg motiva VIIl toksina A (amino-kiselina 2665-2686) i drugi proksimalni kraj je u oviru kratkog ponovka 3 ponavljajućeg motiva l toksina B (1877-1896).
- 20. Polipeptid prema bilo kom od zahteva 1-8, 9, 10, 11, 12 i 15, gde je prvi proksimalni kraj u okviru kratkog ponovka 3 ponavljajućeg motiva VIlI toksina A (amino-kiselina 2645-2686) i drugi proksimalni kraj je u okviru kratkog ponovkal ponavljajućeg motiva l toksina B (amino kiselina 1834-1854).
- 21. Polipeptid prema bilo kom od zahteva 9, 10, 13 ili 14, gde je prvi proksimalni kraj u okviru kratkog ponovka 3 ponavljajućeg motiva VIlI toksina A (amino-kiseline 2687-2710) i drugi proksimalni kraj je u okviru kratkog ponovka 4 ponavljajućeg motiva ll toksina B (amino kiseline 1988-2007).
- 22. Polipeptid prema zahtevu 16, gde je prvi proksimalni kraj u okviru amino-kiselina 2700-2710 toksina A i drugi proksimalni kraj je u okviru amino-kiselina 1960-1970 toksina B.
- 23. Polipeptid prema zahtevu 16, gde je prvi proksimalni kraj u ovkiru amino-kiselina 2680-2690 toksina A i drugi proksimalni kraj je u okviru amin -kiselina 1960-1970 toksina B.
- 24. Polipeptid prema zahtevu 16, gde je prvi proksimalni kraj u okviru amino-kiselina 2700-2710 toksina A i drugi proksimalni kraj je u okviru amino-kiselina 1988-1998 toksina B.
- 25. Polipeptid prema zahtevu 16, u kome je prvi proksimalni kraj u okviru amino-kiselina 2680-2690 i drugi proksimalni kraj je u okviru amino-kiselina 1860-1878.
- 26. Polipeptid prema bilo kom prethodnom zahtevu gde je polipeptid deo većeg fuzionog proteina.
- 27. Polipeptid prema bilo kom prethodnom zahtevu, gde polipeptid sadrži imunogeni fragment SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:6, SEQ ID N0:7 SEQ ID N0:21, SEQ ID N0:23, SEQ ID N0:25 ili SEQ ID N0:27.
- 28. Polipeptid prema bilo kom zahtevu, gde polipeptid sadrži imunogeni fragment od bar 500, 600, 700, 750,800,850 ili 900 amino-kiselina SEQ ID N0:3,SEQ ID N0:4, SEQ ID N0:6,SEQ ID N0:7 SEQ ID N0:21, SEQ ID N0:23, SEQ ID N0:25 ili SEQ ID N0:27.
- 29. Polipeptid prema bilo kom prethodnom zahtevu gde polipeptid sadrži više od 450, 475, 500 ,525,575,600,625, 650,675,700, 725,750,775,800, 825 ili 850 amino-kiselina iz toksina A.
- 30. Polipeptid prema bilo kom prethodnom zahtevu, gde polipeptid sadrži manje od 850, 825, 800, 775,750,725,700,675,650, 625,ili 600 amino-kiselina toksina A.
- 31. Polipeptid prema bilo kom prethodnom zahtevu,gde polipeptid sadrži više od 350, 375,400, 425,450, 475, 500 ili 525 amino-kiselina iz toksina B.
- 32. Polipeptid prema bilo kom prethodnom zahtevu, gde polipeptid sadrži manje od 525, 500,475, ili 450 amino-kiselina toksina B.
- 33. Polinukleotid koji kodira polipeptid prema bilo kom od zahteva 1-32.
- 34. Vektor koji sadrži polinukleotid prema zahtevu 33 vezan za inducibilni promoter.
- 35. lmunogena kompozicija koja sadrži polipeptid prema bilo kom od zahteva 1-32 i farmaceutski prihvatljiv ekscipijent.
- 36. lmunogena kompozicija prema zahtevu 35 koja dalje sadrži pomoćno sredstvo.
- 37. lmunogena kompozcija prema bilo kom od zahteva 35-36 što dalje sadrži dodatne antigene.
- 38. lmunogena kompozicija prema zahtevu 37, što su dodatni antigeni antigeni koji potiču iz bakterija izabranih iz grupe koju čine S.pneumoniae, H.influenzae, N.meningitidis, E.coli, M.cattarhalis, tetanus,difterija,veliki kašalj,S.epidermidis, enterokoke, i S.aureus.
- 39. Vakcina koja sadrži imunogenu kompoziciju prema bilo kom od zahteva 35-38.
- 40. lmunogena kompozicija prema bilo kom od zahteva 35-38 ili vakcina prema zahtevu 39 za upotrebu u lečenju ili prevencijibolestiizazvane sa C.difficile.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490716P | 2011-05-27 | 2011-05-27 | |
| US201161490707P | 2011-05-27 | 2011-05-27 | |
| US201161490734P | 2011-05-27 | 2011-05-27 | |
| EP12726374.7A EP2714911B1 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
| PCT/EP2012/059805 WO2012163817A2 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02600B true ME02600B (me) | 2017-06-20 |
Family
ID=46168484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-26A ME02600B (me) | 2011-05-27 | 2012-05-25 | Imunogena kompozicija |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9290565B2 (me) |
| EP (6) | EP4296361A3 (me) |
| JP (3) | JP5952390B2 (me) |
| KR (1) | KR102014502B1 (me) |
| CN (3) | CN103717742B (me) |
| BR (2) | BR112013030396A2 (me) |
| CA (2) | CA2837395C (me) |
| CY (3) | CY1118599T1 (me) |
| DK (4) | DK2714910T3 (me) |
| EA (1) | EA030898B1 (me) |
| ES (4) | ES2968455T3 (me) |
| FI (1) | FI3564378T3 (me) |
| HR (4) | HRP20180339T1 (me) |
| HU (4) | HUE037126T2 (me) |
| IL (1) | IL229529B2 (me) |
| LT (4) | LT2714910T (me) |
| ME (1) | ME02600B (me) |
| MX (1) | MX346200B (me) |
| PL (4) | PL3564378T3 (me) |
| PT (4) | PT2714911T (me) |
| RS (1) | RS55605B1 (me) |
| SG (1) | SG195037A1 (me) |
| SI (4) | SI2714910T1 (me) |
| SM (2) | SMT201700110T1 (me) |
| WO (3) | WO2012163811A1 (me) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033342T2 (en) | 2010-09-03 | 2017-11-28 | Valneva Austria Gmbh | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof |
| HUE047085T2 (hu) | 2011-04-22 | 2020-04-28 | Wyeth Llc | Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai |
| CA2858519A1 (en) | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| DK2928489T3 (en) | 2012-12-05 | 2019-04-23 | Glaxosmithkline Biologicals Sa | IMMUNOGENE COMPOSITION |
| CN105451762A (zh) * | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| CA2976976C (en) | 2015-02-19 | 2023-02-28 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
| CA3102353A1 (en) | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| CZ296806B6 (cs) | 1994-10-24 | 2006-06-14 | Allergan, Inc. | Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu |
| ATE195878T1 (de) * | 1995-07-07 | 2000-09-15 | Oravax Inc | Toxine und toxoide von clostridium difficile als schleimhautadjuvans |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| US20120020996A1 (en) * | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| HUE033342T2 (en) | 2010-09-03 | 2017-11-28 | Valneva Austria Gmbh | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
-
2012
- 2012-05-25 DK DK12724950.6T patent/DK2714910T3/en active
- 2012-05-25 JP JP2014511899A patent/JP5952390B2/ja active Active
- 2012-05-25 DK DK16193340.3T patent/DK3138916T3/da active
- 2012-05-25 HU HUE12724950A patent/HUE037126T2/hu unknown
- 2012-05-25 RS RS20170051A patent/RS55605B1/sr unknown
- 2012-05-25 PT PT127263747T patent/PT2714911T/pt unknown
- 2012-05-25 WO PCT/EP2012/059793 patent/WO2012163811A1/en not_active Ceased
- 2012-05-25 PL PL19179871.9T patent/PL3564378T3/pl unknown
- 2012-05-25 CN CN201280037472.3A patent/CN103717742B/zh active Active
- 2012-05-25 LT LTEP12724950.6T patent/LT2714910T/lt unknown
- 2012-05-25 CN CN201280037466.8A patent/CN103732750A/zh active Pending
- 2012-05-25 MX MX2013013924A patent/MX346200B/es active IP Right Grant
- 2012-05-25 PL PL16193340T patent/PL3138916T3/pl unknown
- 2012-05-25 LT LTEP12726374.7T patent/LT2714911T/lt unknown
- 2012-05-25 WO PCT/EP2012/059792 patent/WO2012163810A1/en not_active Ceased
- 2012-05-25 DK DK19179871.9T patent/DK3564378T5/da active
- 2012-05-25 SG SG2013085386A patent/SG195037A1/en unknown
- 2012-05-25 EA EA201391548A patent/EA030898B1/ru not_active IP Right Cessation
- 2012-05-25 EP EP23205566.5A patent/EP4296361A3/en active Pending
- 2012-05-25 US US14/122,690 patent/US9290565B2/en not_active Expired - Fee Related
- 2012-05-25 PT PT191798719T patent/PT3564378T/pt unknown
- 2012-05-25 WO PCT/EP2012/059805 patent/WO2012163817A2/en not_active Ceased
- 2012-05-25 SI SI201231247T patent/SI2714910T1/en unknown
- 2012-05-25 SI SI201232050T patent/SI3564378T1/sl unknown
- 2012-05-25 SI SI201230868A patent/SI2714911T1/sl unknown
- 2012-05-25 HU HUE16193340 patent/HUE044772T2/hu unknown
- 2012-05-25 KR KR1020137034795A patent/KR102014502B1/ko active Active
- 2012-05-25 EP EP19179871.9A patent/EP3564378B1/en not_active Revoked
- 2012-05-25 ES ES19179871T patent/ES2968455T3/es active Active
- 2012-05-25 ES ES12726374.7T patent/ES2615737T3/es active Active
- 2012-05-25 CA CA2837395A patent/CA2837395C/en active Active
- 2012-05-25 EP EP12726374.7A patent/EP2714911B1/en not_active Revoked
- 2012-05-25 PT PT16193340T patent/PT3138916T/pt unknown
- 2012-05-25 PL PL12726374T patent/PL2714911T3/pl unknown
- 2012-05-25 BR BR112013030396A patent/BR112013030396A2/pt not_active IP Right Cessation
- 2012-05-25 EP EP16193340.3A patent/EP3138916B1/en not_active Revoked
- 2012-05-25 EP EP18150735.1A patent/EP3327126A1/en not_active Withdrawn
- 2012-05-25 DK DK12726374.7T patent/DK2714911T3/en active
- 2012-05-25 CN CN201710239709.0A patent/CN107098977A/zh active Pending
- 2012-05-25 ES ES12724950.6T patent/ES2660468T3/es active Active
- 2012-05-25 FI FIEP19179871.9T patent/FI3564378T3/fi active
- 2012-05-25 HR HRP20180339TT patent/HRP20180339T1/hr unknown
- 2012-05-25 SI SI201231642T patent/SI3138916T1/sl unknown
- 2012-05-25 PL PL12724950T patent/PL2714910T3/pl unknown
- 2012-05-25 HR HRP20231749TT patent/HRP20231749T1/hr unknown
- 2012-05-25 CA CA2837393A patent/CA2837393A1/en not_active Abandoned
- 2012-05-25 ES ES16193340T patent/ES2743442T3/es active Active
- 2012-05-25 HR HRP20170094TT patent/HRP20170094T1/hr unknown
- 2012-05-25 PT PT127249506T patent/PT2714910T/pt unknown
- 2012-05-25 LT LTEP19179871.9T patent/LT3564378T/lt unknown
- 2012-05-25 SM SM20170110T patent/SMT201700110T1/it unknown
- 2012-05-25 EP EP12724950.6A patent/EP2714910B1/en active Active
- 2012-05-25 LT LTEP16193340.3T patent/LT3138916T/lt unknown
- 2012-05-25 ME MEP-2017-26A patent/ME02600B/me unknown
- 2012-05-25 BR BR112013030395-6A patent/BR112013030395B1/pt active IP Right Grant
- 2012-05-25 US US14/122,345 patent/US9409974B2/en active Active
- 2012-05-25 HU HUE19179871A patent/HUE064492T2/hu unknown
- 2012-05-25 HU HUE12726374A patent/HUE030823T2/en unknown
- 2012-05-25 JP JP2014511895A patent/JP2014516532A/ja active Pending
-
2013
- 2013-11-21 IL IL229529A patent/IL229529B2/en unknown
-
2016
- 2016-02-11 US US15/041,924 patent/US9644024B2/en not_active Expired - Fee Related
- 2016-06-09 JP JP2016114910A patent/JP2017012160A/ja active Pending
- 2016-06-28 US US15/194,937 patent/US10093722B2/en active Active
-
2017
- 2017-02-03 CY CY20171100158T patent/CY1118599T1/el unknown
- 2017-02-16 SM SM201700110T patent/SMT201700110B/it unknown
- 2017-03-21 US US15/464,454 patent/US10377816B2/en active Active
-
2018
- 2018-02-15 CY CY20181100188T patent/CY1119916T1/el unknown
-
2019
- 2019-07-17 HR HRP20191291TT patent/HRP20191291T1/hr unknown
- 2019-08-27 CY CY20191100909T patent/CY1121936T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02600B (me) | Imunogena kompozicija | |
| HRP20200727T1 (hr) | Pripravci i metode povezane s varijantama proteina a (spa) | |
| JP2009540801A5 (me) | ||
| WO2011068953A3 (en) | Atoxic recombinant holotoxins of clostridium difficile as immunogens | |
| HRP20161305T1 (hr) | Liječenje mikrobnih infekcija | |
| IL276210B2 (en) | Mers-cov vaccine | |
| Moreira et al. | Production of recombinant botulism antigens: A review of expression systems | |
| HRP20161608T1 (hr) | Modificirani tuberkulozni antigeni | |
| US10588955B2 (en) | Streptococcus pneumoniae protein antigen, and preparation method and use thereof | |
| JP2013523718A5 (me) | ||
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| JP2013520487A5 (me) | ||
| JP2016504993A5 (me) | ||
| Langroudi et al. | Expression of Clostridium perfringens epsilon-beta fusion toxin gene in E. coli and its immunologic studies in mouse | |
| JP2016514713A5 (me) | ||
| CN113366016A (zh) | 抗人白细胞介素5(il-5)单克隆抗体及其应用 | |
| HRP20230694T1 (hr) | Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para | |
| HRP20211838T1 (hr) | Krnji protein vp4 rotavirusa i njegova primjena | |
| JP2017513849A5 (me) | ||
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP2015529677A5 (me) | ||
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine | |
| AU2011304942B2 (en) | Fusion protein SAmB, coding gene and application thereof | |
| JP2015524420A5 (me) | ||
| Chen et al. | Designing, expression and immunological characterization of a chimeric protein of Mycoplasma pneumoniae |